Related Experiment Video
Updated: Dec 30, 2025

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
Published on: October 3, 2011
R-Roscovitine Improves Motoneuron Function in Mouse Models for Spinal Muscular Atrophy.
Rocio Tejero1, Stefanie Balk2, Julio Franco-Espin1
1Department of Medical Physiology and Biophysics, School of Medicine, University of Seville, 41009 Seville, Spain.
R-Roscovitine treatment significantly improved survival and motor function in spinal muscular atrophy (SMA) mice by enhancing calcium signaling and motor neuron health. This drug offers a promising therapeutic avenue for SMA by restoring neuromuscular junction function.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Spinal muscular atrophy (SMA) is a genetic disease characterized by motoneuron degeneration and neurotransmission defects, primarily due to SMN protein deficiency.
- Motoneuron dysfunction and impaired neuromuscular junctions are key pathological features of SMA, leading to progressive muscle weakness.
Purpose of the Study:
- To investigate the therapeutic potential of R-Roscovitine, a Cav2.1/Cav2.2 channel modifier and Cdk-5 inhibitor, in a mouse model of SMA.
- To elucidate the mechanisms by which R-Roscovitine affects calcium signaling and neuromuscular junction function in Smn-deficient motoneurons.
Main Methods:
- Systemic administration of R-Roscovitine to SMA mice.
- In vitro studies using Smn-deficient motoneurons to assess axon growth, growth cone size, and calcium (Ca2+) influx.
- Electrophysiological analysis of neuromuscular junctions to evaluate neurotransmitter release and synaptic activity.
Main Results:
- R-Roscovitine treatment significantly increased survival rates in SMA mice.
- The drug enhanced Cav2.1 channel density and motor endplate size, improving neuromuscular junction morphology.
- In vitro, R-Roscovitine restored motoneuron axon length and growth cone size, mediated by enhanced Ca2+ influx and Cav2.2 channel clustering, independent of Cdk-5 inhibition.
- Acute R-Roscovitine application increased evoked neurotransmitter release, spontaneous miniature potential frequency, and reduced the activation threshold of silent terminals.
Conclusions:
- R-Roscovitine demonstrates significant therapeutic benefits in SMA, improving survival and neuromuscular function.
- The drug enhances Ca2+ signaling and homeostasis in Smn-deficient motoneurons, crucial for their differentiation, maturation, and function.
- R-Roscovitine represents a potential therapeutic strategy for SMA by targeting calcium channel modulation and restoring synaptic function.
More Related Videos
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
10:57Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons
Published on: July 13, 2015